These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21613036)

  • 1. Pharmacovigilance in clinical dentistry: overlooked or axiomatic?
    Carnelio S; Khan SA; Rodrigues G
    Gen Dent; 2011; 59(1):24-8; quiz 29-30, 80. PubMed ID: 21613036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacovigilance: a case of phantom ships and Russian roulette].
    Stricker BH
    Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 5. [The need for 'postmarketing surveillance'].
    Stricker BH; in 't Veld BA; Feenstra J
    Ned Tijdschr Geneeskd; 1999 Apr; 143(14):711-3. PubMed ID: 10347624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 7. The knowledge, perceptions and practice of pharmacovigilance amongst community pharmacists in Lagos state, south west Nigeria.
    Oreagba IA; Ogunleye OJ; Olayemi SO
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):30-5. PubMed ID: 20845410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 9. Consumer groups look to improve adverse event reporting systems.
    Vastag B
    J Natl Cancer Inst; 2005 Dec; 97(24):1804-5. PubMed ID: 16368939
    [No Abstract]   [Full Text] [Related]  

  • 10. An overview of spontaneous reporting of adverse drug reactions (ARDs) in Zimbabwe.
    Ball D
    Cent Afr J Med; 2000 Jan; 46(1):23-4. PubMed ID: 14674204
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 12. [PSUR - Instrument for pharmacovigilance and patient safety. What pharmacists should know about periodic safety update reports].
    Strehl E
    Med Monatsschr Pharm; 2009 Sep; 32(9):347-9. PubMed ID: 19795697
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacovigilance in pharmacy practice].
    Duquet N
    J Pharm Belg; 2011 Dec; (4):97-103. PubMed ID: 22299235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reporting adverse effects: a practice to be encouraged.
    Prescrire Int; 2013 Mar; 22(136):83. PubMed ID: 23593701
    [No Abstract]   [Full Text] [Related]  

  • 15. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?
    Trifirò G; Pariente A; Coloma PM; Kors JA; Polimeni G; Miremont-Salamé G; Catania MA; Salvo F; David A; Moore N; Caputi AP; Sturkenboom M; Molokhia M; Hippisley-Cox J; Acedo CD; van der Lei J; Fourrier-Reglat A;
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1176-84. PubMed ID: 19757412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model for the future conduct of pharmacovigilance.
    Waller PC; Evans SJ
    Pharmacoepidemiol Drug Saf; 2003; 12(1):17-29. PubMed ID: 12616844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adverse events related to substitution of generic products in Norway 2005].
    Reppe LA; Stenberg-Nilsen H; Harg P; Hegge AB; Lillefloth AK; Buajordet I
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2696-700. PubMed ID: 19079413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 20. European drug agency criticises Roche for failing to report adverse reactions and patient deaths.
    Wise J
    BMJ; 2012 Jun; 344():e4344. PubMed ID: 22736470
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.